Top

Published in:

Open Access 01-07-2019 | Helicobacter Pylori | Review

Association between atrial fibrillation and Helicobacter pylori

Authors: Cecilia Tetta, Amalia Ioanna Moula, Francesco Matteucci, Orlando Parise, Bart Maesen, Daniel Johnson, Mark La Meir, Sandro Gelsomino

Published in: Clinical Research in Cardiology | Issue 7/2019

Abstract

The connection between atrial fibrillation (AF) and H. pylori (HP) infection is still matter of debate. We performed a systematic review and metanalysis of studies reporting the association between AF and HF. A systematic review of all available reports in literature of the incidence of HP infection in AF and comparing this incidence with subjects without AF were analysed. Risk ratio and 95% confidence interval (CI) and risk difference with standard error (SE) were the main statistics indexes. Six retrospective studies including a total of 2921 were included at the end of the selection process. Nine hundred-fifty-six patients (32.7%) were in AF, whereas 1965 (67.3%) were in normal sinus rhythm (NSR). Overall, 335 of 956 patients with AF were HP positive (35%), whereas 621 were HP negative (65%). In addition, 643 of 1965 NSR patients (32.7%) were HP positive while 1,322 were negative (67.3%; Chi-square 2.15, p = 0.21). The Cumulative Risk Ratio for AF patients for developing an HP infection was 1.19 (95% CI 1.08–1.41). In addition, a small difference risk towards AF was found (0.11 [SE = 0.04]). Moreover, neither RR nor risk difference were influenced by the geographic area at meta-regression analysis. Finally, there was a weak correlation between AF and HP (coefficient = 0.04 [95% CI −0.01–0.08]). We failed to find any significant correlation between H. pylori infection and AF and, based on our data, it seems unlikely than HP can be considered a risk factor for AF. Further larger research is warranted.

Abdin A, Yalin K, Lyan E, Sawan N, Liosis S, Meyer-Saraei R, Elsner C, Lange SA, Heeger C-H, Eitel C, Eitel I, Tilz RR (2018) Safety and efficacy of cryoballoon ablation for the treatment of atrial fibrillation in elderly patients. Clin Res Cardiol

Bettin M, Dechering D, Kochhauser S, Bode N, Eckardt L, Frommeyer G, Reinke F (2018) Extended ECG monitoring with an implantable loop recorder in patients with cryptogenic stroke: time schedule, reasons for explantation and incidental findings (results from the TRACK-AF trial). Clin Res Cardiol

Feyz L, Theuns DA, Bhagwandien R, Strachinaru M, Kardys I, Van Mieghem NM, Daemen J (2018) Atrial fibrillation reduction by renal sympathetic denervation: 12 months’ results of the AFFORD study. Clin Res Cardiol

Halbfass P, Sonne K, Nentwich K, Ene E, Deneke T (2018) Current developments in cardiac rhythm management devices. Clin Res Cardiol 107:100–104CrossRefPubMed

Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, Chan FKL, Sung JJY, Kaplan GG, Ng SC (2017) Global prevalence of helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 153:420–429CrossRef

Jobs A, Schwind J, Katalinic A, Babaev V, Tilz RR, Rausch S, Thiele H, Eitel I, Eitel C (2018) Prognostic significance of atrial fibrillation in acute decompensated heart failure with reduced versus preserved ejection fraction. Clin Res Cardiol

Kottmaier M, Jilek C, Berglar S, Reents T, Bourier F, Semmler V, Telishevska M, Koch-Buttner K, Lengauer S, Kornmayer M, Rousseva E, Brooks S, Hadamitzky M, Kolb C, Hessling G, Deisenhofer I (2018) Exclusion of left atrial thrombus by dual-source cardiac computed tomography prior to catheter ablation for atrial fibrillation. Clin Res Cardiol

Liu D, Hu K, Schmidt M, Muntze J, Maniuc O, Gensler D, Oder D, Salinger T, Weidemann F, Ertl G, Frantz S, Wanner C, Nordbeck P (2018) Value of the CHA2DS2-VASc score and fabry-specific score for predicting new-onset or recurrent stroke/TIA in Fabry disease patients without atrial fibrillation. Clin Res Cardiol 107:1111–1121CrossRefPubMedPubMedCentral

Myrstad M, Malmo V, Ulimoen SR, Tveit A, Loennechen JP (2018) Exercise in individuals with atrial fibrillation. Clin Res Cardiol

10.

Prochaska JH, Gobel S, Nagler M, Knopfler T, Eggebrecht L, Lamparter H, Panova-Noeva M, Keller K, Coldewey M, Bickel C, Lauterbach M, Hardt R, Espinola-Klein C, Ten Cate H, Rostock T, Munzel T, Wild PS (2018) Sustained atrial fibrillation increases the risk of anticoagulation-related bleeding in heart failure. Clin Res Cardiol 107:1170–1179CrossRefPubMed

11.

Romero R, Gaytan JM, Aguirre A, Llorens P, Gil V, Herrero P, Jacob J, Martin-Sanchez FJ, Perez-Dura MJ, Alquezar A, Lopez ML, Roset A, Peacock WF, Hollander JE, Coll-Vinent B, Miro O and Group I-SR (2018) The role of atrial fibrillation in the short-term outcomes of patients with acute heart failure. Clin Res Cardiol

12.

Semmler V, von Krogh F, Haller B, Reents T, Bourier F, Telishevska M, Kottmaier M, Kornmayer M, Brooks S, Koch-Buttner K, Lennerz C, Brkic A, Grebmer C, Blazek P, Weigand S, Hessling G, Kolb C, Deisenhofer I (2018) The incidence, indications and predictors of acute pacemaker implantation after ablation of persistent atrial fibrillation. Clin Res Cardiol

13.

Shoaib A, Farag M, Nolan J, Rigby A, Patwala A, Rashid M, Kwok CS, Perveen R, Clark AL, Komajda M, Cleland JGF (2018) Mode of presentation and mortality amongst patients hospitalized with heart failure? A report from the First Euro Heart Failure Survey. Clin Res Cardiol

14.

Sramko M, Wichterle D, Melenovsky V, Franekova J, Clemens M, Fukunaga M, Kautzner J (2018) Independent effect of atrial fibrillation on natriuretic peptide release. Clin Res Cardiol

15.

Thomas D, Christ T, Fabritz L, Goette A, Hammwohner M, Heijman J, Kockskamper J, Linz D, Odening KE, Schweizer PA, Wakili R, Voigt N, German Cardiac Society Working Group on (2018) Cellular electrophysiology state-of-the-art paper: impact of molecular mechanisms on clinical arrhythmia management. Clin Res Cardiol

16.

van den Bruck J-H, Sultan A, Luker J, Thomas D, Willems S, Weinmann K, Kuniss M, Hochadel M, Senges J, Andresen D, Brachmann J, Kuck K-H, Tilz R, Steven D (2018) Remote vs. conventional navigation for catheter ablation of atrial fibrillation: insights from prospective registry data. Clin Res Cardiol

17.

Wasmer K, Hochadel M, Wieneke H, Spitzer SG, Brachmann J, Straube F, Tebbenjohanns J, Groschup G, Heisel A, Lewalter T, Senges J, Eckardt L (2018) Long-term symptom improvement and patient satisfaction after AV-node ablation vs. pulmonary vein isolation for symptomatic atrial fibrillation: results from the German Ablation Registry. Clin Res Cardiol

18.

Bellmann B, Lin T, Ruppersberg P, Zettwitz M, Guttmann S, Tscholl V, Nagel P, Roser M, Landmesser U, Rillig A (2018) Identification of active atrial fibrillation sources and their discrimination from passive rotors using electrographical flow mapping. Clin Res Cardiol

19.

Duerschmied D, Brachmann J, Darius H, Frey N, Katus HA, Rottbauer W, Schafer A, Thiele H, Bode C, Zeymer U (2018) Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials? Clin Res Cardiol 107:533–538CrossRefPubMed

20.

Linz D, Arzt M, Sanders P, Bohm M (2018) Should we treat any sleep apnea in patients with atrial fibrillation? Clin Res Cardiol

21.

Maurer T, Rottner L, Makimoto H, Reissmann B, Heeger CH, Lemes C, Fink T, Riedl J, Santoro F, Wohlmuth P, Volkmer M, Mathew S, Metzner A, Ouyang F, Kuck KH, Sohns C (2018) The best of two worlds? Pulmonary vein isolation using a novel radiofrequency ablation catheter incorporating contact force sensing technology and 56-hole porous tip irrigation. Clin Res Cardiol

22.

Murray MI, Arnold A, Younis M, Varghese S, Zeiher AM (2018) Cryoballoon versus radiofrequency ablation for paroxysmal atrial fibrillation: a meta-analysis of randomized controlled trials. Clin Res Cardiol 107:658–669CrossRefPubMed

23.

Omran H, Gutleben KJ, Molatta S, Fischbach T, Wellmann B, Horstkotte D, Korber B, Nolker G (2018) Second generation cryoballoon ablation for persistent atrial fibrillation: an updated meta-analysis. Clin Res Cardiol 107:182–192CrossRefPubMed

24.

Pastori D, Miyazawa K, Li Y, Shahid F, Hado H, Lip GYH (2018) Inflammation and the risk of atrial high-rate episodes (AHREs) in patients with cardiac implantable electronic devices. Clin Res Cardiol 107:772–777CrossRefPubMedPubMedCentral

25.

Desteghe L, Hendriks JML, McEvoy RD, Chai-Coetzer CL, Dendale P, Sanders P, Heidbuchel H, Linz D (2018) The why, when and how to test for obstructive sleep apnea in patients with atrial fibrillation. Clin Res Cardiol 107:617–631CrossRefPubMed

26.

Haeusler KG, Groschel K, Kohrmann M, Anker SD, Brachmann J, Bohm M, Diener HC, Doehner W, Endres M, Gerloff C, Huttner HB, Kaps M, Kirchhof P, Nabavi DG, Nolte CH, Pfeilschifter W, Pieske B, Poli S, Schabitz WR, Thomalla G, Veltkamp R, Steiner T, Laufs U, Rother J, Wachter R, Schnabel R (2018) Expert opinion paper on atrial fibrillation detection after ischemic stroke. Clin Res Cardiol 107:871–880CrossRefPubMed

27.

Chugh SS, Roth GA, Gillum RF, Mensah GA (2014) Global burden of atrial fibrillation in developed and developing nations. Glob Heart 9:113–119CrossRefPubMed

28.

Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T (2006) Lip GY and Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 27:949–953CrossRefPubMed

29.

Ringborg A, Lindgren P, Jonsson B (2005) The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. Eur J Health Econ 6:354–356, (358 – 62)CrossRefPubMed

30.

Kannel WB, Wolf PA, Benjamin EJ, Levy D (1998) Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82:2N–9NCrossRefPubMed

31.

Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S (2014) Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 6:213–220CrossRefPubMedPubMedCentral

32.

Iwasaki YK, Nishida K, Kato T, Nattel S (2011) Atrial fibrillation pathophysiology: implications for management. Circulation 124:2264–2274CrossRefPubMed

33.

Guo Y, Lip GY, Apostolakis S (2012) Inflammation in atrial fibrillation. J Am Coll Cardiol 60:2263–2270CrossRef

34.

Anter E, Jessup M, Callans DJ (2009) Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation 119:2516–2525CrossRefPubMed

35.

Ferreira C, Providencia R, Ferreira MJ, Goncalves LM (2015) Atrial fibrillation and non-cardiovascular diseases: a systematic review. Arq Bras Cardiol 105:519–526PubMedPubMedCentral

36.

Gesualdo M, Scicchitano P, Carbonara S, Ricci G, Principi M, Ierardi E, Di Leo A, Cortese F, Ciccone MM (2016) The association between cardiac and gastrointestinal disorders: causal or casual link? J Cardiovasc Med (Hagerstown) 17:330–338CrossRef

37.

Montenero AS, Mollichelli N, Zumbo F, Antonelli A, Dolci A, Barberis M, Sirolla C, Staine T, Fiocca L, Bruno N, O’Connor S (2005) Helicobacter pylori and atrial fibrillation: a possible pathogenic link. Heart 91:960–961CrossRefPubMedPubMedCentral

38.

Andrew P, Montenero AS (2006) Is Helicobacter pylori a cause of atrial fibrillation? Fut Cardiol 2:429–439CrossRef

39.

Andrew P, Montenero AS (2007) Is there a link between atrial fibrillation and certain bacterial infections? J Cardiovasc Med (Hagerstown) 8:990–996CrossRef

40.

Lunetta M, Fazio G, Avena V, Corrado E, Loredana S, Arnone E, Novo G, Novo S (2009) Helicobacter pylori and atrial fibrillation: absence of correlations. J Cardiovasc Med (Hagerstown) 10:4–5CrossRef

41.

Platonov P, Ekesbo R, Hansson A, Andsberg E, Meurling CJ, Nilsson I, Ljungh A, Wadstrom T, Olsson SB (2008) Permanent atrial fibrillation in patients without structural heart disease is not associated with signs of infection by Chlamydia pneumoniae and Helicobacter pylori. Acta Cardiol 63:479–484CrossRefPubMed

42.

Yan J, She Q, Zhang Y, Cui C, Zhang G (2016) The association between arrhythmia and helicobacter pylori Infection: a meta-analysis of case–control studies. Int J Environ Res Public Health 13

43.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–e34CrossRef

44.

Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan A-W, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919CrossRefPubMedPubMedCentral

45.

Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Commun Health 52:377–384CrossRef

46.

Hughes A, Hirsch C, Chalder T, Moss-Morris R (2016) Attentional and interpretive bias towards illness-related information in chronic fatigue syndrome: a systematic review. Br J Health Psychol 21:741–763CrossRefPubMed

47.

Byrt T, Bishop J, Carlin JB (1993) Bias, prevalence and kappa. J Clin Epidemiol 46:423–429CrossRef

48.

McHugh ML (2012) Interrater reliability: the kappa statistic. Biochem Med 22:276–282CrossRef

49.

Garza-Gonzalez E, Perez-Perez GI, Maldonado-Garza HJ, Bosques-Padilla FJ (2014) A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. World J Gastroenterol 20:1438–1449CrossRefPubMedPubMedCentral

50.

Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ Br Med J 327:557–560CrossRef

51.

Schmidt F, Hunter LJE (2015) Methods of metha-analysis. SAGE, Thausand Oaks

52.

Bunch TJ, Day JD, Anderson JL, Horne BD, Muhlestein JB, Crandall BG, Weiss JP, Lappe DL, Asirvatham SJ (2008) Frequency of helicobacter pylori seropositivity and C-reactive protein increase in atrial fibrillation in patients undergoing coronary angiography. Am J Cardiol 101:848–851CrossRefPubMed

53.

Badran HM, Mahfouz ME (2007) Cytotoxin-associated gene-A bearing strains of Helicobacter pylori and atrial fibrillation due to ischemic origin: is there a link? Eur J Cardiovasc Prev Rehabil 14:518–520CrossRefPubMed

54.

Ki M-R, Shin D-G, Park J-S, Hong K-S, Hong I-H, Park J-K, Jeong K-S (2010) Frequency of vacuolating cytotoxin A (VacA)-positive Helicobacter pylori seropositivity and TGF-beta1 decrease in atrial fibrillation. Int J Cardiol 145:345–346CrossRefPubMed

55.

Franceschi F, Brisinda D, Buccelletti F, Ruggieri MP, Gasbarrini A, Sorbo A, Marsiliani D, Venuti A, Fenici P, Gasbarrini G, Silveri NG, Fenici R (2013) Prevalence of virulent Helicobacter pylori strains in patients affected by idiopathic dysrhythmias. Intern Emerg Med 8:333–337CrossRefPubMed

56.

Wang D-Z, Chen W, Yang S, Wang J, Li Q, Fu Q, Li S-J, Chen B-X (2015) Helicobacter pylori infection in Chinese patients with atrial fibrillation. Clin Interv Aging 10:813–819CrossRefPubMedPubMedCentral

57.

de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13:607–615CrossRefPubMed

58.

Suerbaum S, Michetti P (2002) Helicobacter pylori infection. N Engl J Med 347:1175–1186CrossRefPubMed

59.

Boos CJ, Anderson RA, Lip GYH (2006) Is atrial fibrillation an inflammatory disorder? Eur Heart J 27:136–149CrossRef

60.

Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DT (2005) Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 95:764–767CrossRefPubMed

61.

Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR (2001) C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104:2886–2891CrossRefPubMed

62.

Marcus GM, Whooley MA, Glidden DV, Pawlikowska L, Zaroff JG, Olgin JE (2008) Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am Heart J 155:303–309CrossRefPubMed

63.

Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, Chugh SS, Corradi D, D’Avila A, Dobrev D, Fenelon G, Gonzalez M, Hatem SN, Helm R, Hindricks G, Ho SY, Hoit B, Jalife J, Kim Y-H, Lip GYH, Ma C-S, Marcus GM, Murray K, Nogami A, Sanders P, Uribe W, Van Wagoner DR, Nattel S (2016) Document reviewers: Osmar A. Centurion K-HKKKPJLSMSJHS, Gaurav AU and Review coordinator: Alena S. EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: definition, characterisation, and clinical implication. J Arrhythm 32:247–278CrossRefPubMedPubMedCentral

64.

Mishima RS, Elliott AD, Sanders P, Linz D (2018) Microbiome and atrial fibrillation. Int J Cardiol 255:103–104CrossRefPubMed

65.

Yu L, Meng G, Huang B, Zhou X, Stavrakis S, Wang M, Li X, Zhou L, Wang Y, Wang M, Wang Z, Deng J, Po SS, Jiang H (2018) A potential relationship between gut microbes and atrial fibrillation: Trimethylamine N-oxide, a gut microbe-derived metabolite, facilitates the progression of atrial fibrillation. Int J Cardiol 255:92–98CrossRefPubMed

66.

Hatzinikolaou-Kotsakou E, Tziakas D, Hotidis A, Stakos D, Floros D, Papanas N, Chalikias G, Maltezos E, Hatseras DI (2006) Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. Am J Cardiol 97:659–661CrossRefPubMed

67.

Andersen LP (2007) Colonization and Infection by Helicobacter pylori in Humans. Helicobacter 12:12–15CrossRefPubMed

68.

Morillo CA, Banerjee A, Perel P, Wood D, Jouven X (2017) Atrial fibrillation: the current epidemic. J Geriatr Cardiol JGC 14:195–203PubMed

69.

Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim Y-H, McAnulty JH, Zheng Z-J, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJL (2014) Worldwide epidemiology of atrial fibrillation. Circulation 129:837–847CrossRef

Title: Association between atrial fibrillation and Helicobacter pylori
Authors: Cecilia Tetta
Amalia Ioanna Moula
Francesco Matteucci
Orlando Parise
Bart Maesen
Daniel Johnson
Mark La Meir
Sandro Gelsomino
Publication date: 01-07-2019
Publisher: Springer Berlin Heidelberg
Keywords: Helicobacter Pylori
Atrial Fibrillation
Published in: Clinical Research in Cardiology / Issue 7/2019
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-019-01418-w

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Association between atrial fibrillation and Helicobacter pylori

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2019

Retrieval of an embolised occluder with an alligator forceps during staged paravalvular leakage closure

Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation

The impact of biventricular heart failure on outcomes after transcatheter aortic valve implantation

Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial

Variations on classification of main types of myocardial infarction: a systematic review and outcome meta-analysis

Authorship: from credit to accountability. Reflections from the Editors’ Network

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page